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BACKGROUND: Birt–Hogg–Dube´ (BHD) syndrome is an autosomal dominant condition caused by germline FLCN mutations, and
characterised by fibrofolliculomas, pneumothorax and renal cancer. The renal cancer risk, cancer phenotype and pneumothorax risk
of BHD have not yet been fully clarified. The main focus of this study was to assess the risk of renal cancer, the histological subtypes of
renal tumours and the pneumothorax risk in BHD.
METHODS: In this study we present the clinical data of 115 FLCN mutation carriers from 35 BHD families.
RESULTS: Among 14 FLCN mutation carriers who developed renal cancer 7 were o50 years at onset and/or had multifocal/bilateral
tumours. Five symptomatic patients developed metastatic disease. Two early-stage cases were diagnosed by surveillance. The
majority of tumours showed characteristics of both eosinophilic variants of clear cell and chromophobe carcinoma. The estimated
penetrance for renal cancer and pneumothorax was 16% (95% minimal confidence interval: 6–26%) and 29% (95% minimal
confidence interval: 9–49%) at 70 years of age, respectively. The most frequent diagnosis in families without identified FLCN
mutations was familial multiple discoid fibromas.
CONCLUSION: We confirmed a high yield of FLCN mutations in clinically defined BHD families, we found a substantially increased
lifetime risk of renal cancer of 16% for FLCN mutation carriers. The tumours were metastatic in 5 out of 14 patients and tumour
histology was not specific for BHD. We found a pneumothorax risk of 29%. We discuss the implications of our findings for diagnosis
and management of BHD.
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Birt–Hogg–Dube´ syndrome (BHD, OMIM #135150) is an auto-
somal dominant condition characterised by fibrofolliculomas,
pneumothorax and renal tumours. BHD is caused by germline
mutations in the FLCN gene encoding folliculin (Nickerson et al,
2002). In the original kindred skin lesions were the only clinical
manifestation (Birt et al, 1977). Subsequently, renal cancer and
pneumothorax were found to be part of the syndrome (Roth et al,
1993; Toro et al, 1999). Furthermore, the risk for colorectal cancer
might be slightly increased in FLCN mutation carriers (Nahorski
et al, 2010). The functions of folliculin have partly been clarified
and might include a role in the mammalian target of rapamycin
pathway (Hasumi et al, 2009). Although many BHD kindreds
exhibit all three components of the syndrome, ‘pneumothorax-
only’ and ‘renal-cancer-only’ families have also been described
(Graham et al, 2005; Painter et al, 2005; Woodward et al, 2008;
Kunogi et al, 2010). Among 69 patients with early-onset or familial
clear cell renal cancer without further characteristics of BHD,
germline FLCN mutations were found in 4% of cases (Woodward
et al, 2008). In recent reviews, the variable clinical manifestations,
molecular pathogenesis and management options for BHD were
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summarised (Schmidt et al, 2005; Toro et al, 2008; Menko et al,
2009).
For optimal early detection and treatment of BHD-associated
renal cancer, insight into the renal cancer risk and the clinical
picture of these tumours is essential. Among cohorts of BHD
patients a wide range of prevalence of kidney tumours has been
observed, ranging from 6.5 to 34% (Toro et al, 2008). The
differences in prevalence are probably due to ascertainment in
dermatological
vs urological clinics and age at examination. Notably, the lifetime
renal cancer risk for FLCN mutation carriers has not yet been
established. In BHD, renal cancer is generally diagnosed at a
relatively young age and commonly presents as bilateral and/or
multifocal disease. The renal neoplasms typically found in BHD
patients were described as hybrid tumours, containing elements
of different histological subtypes, in particular chromophobe
tumours and oncocytoma. However, other subtypes including clear
cell renal carcinoma have also been reported (Pavlovich et al, 2002,
2005; Schmidt et al, 2005; Woodward et al, 2008).
A 50-fold increased risk of spontaneous pneumothorax in BHD
was reported (Zbar et al, 2002). Among cohorts of BHD patients
the prevalence of pneumothorax ranged from 24 to 38% (Schmidt
et al, 2005; Toro et al, 2007, 2008). Again, ascertainment has varied
for cohorts of patients and the lifetime risk of pneumothorax for
FLCN mutation carriers has not yet been established. On CT
examination of the thorax, more than 80% of adult BHD patients
had multiple lung cysts, most often in the basal lung regions. The
presence of lung cysts is probably related to the increased risk for
pneumothorax, which is often recurrent in BHD patients (Toro
et al, 2007). A positive family history for pneumothorax was
associated with an increased risk of pneumothorax and patients
with a family history positive for renal cancer had an increased
risk of having renal tumours. However, a family history of renal
cancer was not associated with an increased pneumothorax risk
(Toro et al, 2008).
Previously, we described 25 FLCN germline mutation carriers
from 11 BHD families (Leter et al, 2008). Here, we present an
update of this cohort and add the evaluation of 24 new kindreds
with pathogenic FLCN mutations. In total, the clinical histories of
115 FLCN mutation carriers from 35 BHD families have been
assessed. The main focus of this study was to assess the risk of
renal cancer, the histological subtypes of renal tumours and the
pneumothorax risk in BHD. Furthermore, we consider the yield of
FLCN mutation analysis and the clinical phenotype in kindreds
without FLCN mutations.
PATIENTS AND METHODS
Ascertainment of pedigrees
The BHD database at VU University Medical Center currently lists
more than 65 Dutch families referred for suspected BHD; 53 of
these kindreds with completed family studies are considered in
this report. In all, 40 of these 53 families were referred to our
center, whereas other Dutch clinical genetics centers contributed
an additional 13 families with pathogenic FLCN mutations
(Table 1).
The index patient of 48 out of the 53 families was referred by a
dermatologist after fibrofolliculomas were diagnosed. In three
BHD families the index patient had renal cancer (BHD families 33,
35 and 63), in one kindred the proband had recurrent
pneumothorax (BHD 29). One patient without an identifiable
FLCN mutation was referred for multiple pulmonary cysts.
For ascertainment of pedigrees, the proband was requested to
inform family members by means of a written summary letter
about BHD. After completion of the initial evaluation reminders
were sent to probands aimed at complete ascertainment of family
members.
Mutation analysis
After informed consent genomic DNA was extracted from blood
samples. Primers for the amplification and sequencing of the 14
exons were detailed previously by Nickerson et al (2002). PCR
amplification was performed using a PE 9700 thermocycler
(Applied Biosystems, Forster City, CA, USA). Sequencing reactions
were performed using Big Dye Terminator (Applied Biosystems)
and run on an ABI 3100 genetic analyzer (Applied Biosystems). For
the detection of deletions and duplications of one or more exons
the SALSA MLPA kit P256 obtained from MRC Holland was used
(http://www.mrc-holland.com).
Statistical analysis
Conditional on the mutation status for different individuals, we
assumed the various expressions of the BHD phenotype to be
mutually independent and that for individual cases the risks for
renal cancer and pneumothorax and the ages at which these traits
were expressed are independent. Finally, the penetrances of renal
cancer and pneumothorax were assumed to be equal for male and
female mutation carriers.
For the estimates of the penetrance of pneumothorax and renal
cancer we included 21 out of 22 FLCN-positive pedigrees
investigated at our center. For these families medical records of
all mutation carriers and information on untested relatives were
available. Out of these 21 pedigrees, 20 were ascertained via a
proband referred by a dermatologist. One proband (BHD 29) was
referred by a pulmonologist for analysis of recurrent pneumothor-
ax. Therefore, we included the proband data in the estimation of
renal cancer and pneumothorax risks, with the exception of the
proband referred for analysis of pneumothorax.
Major problems of penetrance estimates are missing data and
possible preferential testing of individuals affected with complica-
tions of BHD, that is, renal cancer or pneumothorax. Indeed, if the
mutation status and phenotype had been known for all individuals
in all pedigrees the penetrance curves could have been assessed
using the Kaplan–Meier estimator. Unfortunately, however, the
Table 1 Ascertainment of 115 FLCN mutation carriers from 35 BHD families considered in this study
Subdivision of families Clinical BHD and FLCN mutation Clinical BHD without FLCN mutation Other diagnoses Evaluation declined
40 families referred to our
center for suspected BHDa,b
22 probands and 67 mutation-
positive family members
5 9c 4
13 FLCN-mutation-positive
families from other centres
13 probands and 13 mutation-
positive family members
aIncluding 12 families also described by Leter et al, 2008 and Johannesma et al, 2009. bFor calculation of renal cancer and pneumothorax penetrance the data of 86 FLCN
mutation carriers from 21 kindreds for which complete family data were available were used. cSeven families (11, 17, 20, 24, 38, 45 and 50) had familial multiple discoid fibromas,
described by Starink et al (2011); two index patients (26 and 39) were diagnosed with pulmonary emphysema and probable tuberous sclerosis complex, respectively.
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mutation status or phenotype was not known for all family
members. Excluding the individuals for whom the mutation status
was unknown would likely lead to an overestimation of risk (see
Figure 1A), assuming that non-affected individuals may be less
willing to be genotyped. For our corrected risk estimation we
assumed that a negative family history for renal cancer or
pneumothorax in a close relative indeed reflects the absence of
these complications in the untested relative. We imputed the
missing data as follows: for every individual in the data set who
was not genotyped the probability that he or she was a carrier was
computed on the basis of the mutation status of his/her relatives.
Subsequently, using this carrier probability it was sampled whether
he or she was a mutation carrier or not. As a result, for every
individual the mutation status was assigned and in combination
with the phenotype Kaplan–Meier curves and confidence intervals
were computed. This strategy of sampling the mutation status and
estimating the penetrance functions by the Kaplan–Meier
estimator was repeated 10 000 times. Next, the mean of the
10 000 estimated curves and upper and lower bounds of the
confidence intervals were computed. These curves are plotted in
Figure 1A and B for renal cancer and in Figure 1C for
pneumothorax. By using this strategy the estimator will be
asymptotically unbiased. The confidence interval found is slightly
too narrow because there is a greater degree of uncertainty than
would have been the case if the missing mutation statuses had
actually been observed (as assumed after imputation). Therefore,
the final confidence interval has a confidence of slightly less than
95%. Although the exact confidences of the intervals are not
exactly known we included the calculated intervals in the figures in
order to make those who would use the figures for consultation
aware of the uncertainty of the given risk estimates.
RESULTS
The characteristics of 53 families referred for suspected BHD are
presented in Table 1. The main features of the BHD kindreds with
pathogenic FLCN germline mutations are listed in Table 2. The
mutations detected are depicted in Figure 2. Data on the renal
tumours and pneumothorax are given in Tables 3 and 4,
respectively. Among the 27 families with clinical BHD based on
dermatological evaluation at our center, 22 had pathogenic FLCN
mutations (mutation detection rate 81%). Characteristics of the
five families without a detectable FLCN mutation are summarised
in Table 5; they include two families with an unclassified exon 1
0.4A B C
0.3
0.2
Pr
ob
ab
ilit
y
0.1
0.0
0.4
0.3
0.2
Pr
ob
ab
ilit
y
0.1
0.0
0.5
0.4
0.3
0.2
Pr
ob
ab
ilit
y
0.1
0.0
20 30 40 50 60 70
Age
20 30 40 50 60 70
Age
2010 30 40 50 60 70
Age
Figure 1 (A) Estimate of the age-related penetrance function for renal cancer based on available data on both mutation carriers and their untested
relatives till the age of 70: 16% (continuous line n¼ 86 mutation carriers and 84 untested relatives), together with the Kaplan–Meier estimator based on the
known mutation carriers only at age 70: 20% (n¼ 86, red dashed line). (B) Estimate of the age-related penetrance function for renal cancer based on
available data on both mutation carriers and their untested relatives together with a minimum 95% confidence interval. Estimated penetrance at age 70: 16%,
95% minimal confidence interval: (6-26%). (C) Estimation of the penetrance function of age at the first pneumothorax and a minimum 95% confidence
interval based on available data on both mutation carriers and their untested relatives (n¼ 85 mutation carriers and 84 untested relatives). Estimated
penetrance at age 70: 29%, 95% minimal confidence interval: (9–49%).
Table 2 Main features of 115 FLCN mutation carriers from 35 BHD
kindreds with pathogenic FLCN germline mutations
Family
no.
FLCN germline
mutation
No. of
FLCN
mutation
carriers
No. of
mutation
carriers with
pneumothorax
No. of
mutation
carriers
with
renal
cancer
BHD 1a c.610_611delinsTA 6 2 1
BHD 3a c.420delC 2 0 0
BHD 4a c.1285dupC 1 0 0
BHD 6a c.1285dupC 4 0 2
BHD 8a c.655dupG 2 0 0
BHD 12a c.1285dupC 3 0 0
BHD 14a c.610_611delinsTA 3 1 0
BHD 15a c.619-1G4A 4 1 0
BHD 16a c.610_611delinsTA 18 2 1
BHD 18a c.[1301-7_1304del11;
1323delCinsGA]
2 1 0
BHD 19a c.619-1G4A 1 0 0
BHD 22 c.1285dupC 1 0 0
BHD 23 c.319_320delGTinsCAC 11 1 1
BHD 27 c.1408_1418delGGGAG
CCCTGT
1 0 0
BHD 29b c.610_611delinsTA 2 2 0
BHD 30 c.1285dupC 1 0 0
BHD 31 c.610_611delinsTA 1 0 0
BHD 32 c.469_471delTTC 3 3 1
BHD 33 c.619-1G4A 2 1 1
BHD 35 c.1749_1753del 2 1 1
BHD 36 c.610_611delinsTA 1 0 0
BHD 37 c.319_320delGTinsCAC 15 2 1
BHD 40 c.1183_1198del 1 0 0
BHD 43 c.610_611delinsTA 5 5 2
BHD 44 c.319_320delGTinsCAC 2 0 1
BHD 46 c.1408_1418delGGGAG
CCCTGT
6 0 1
BHD 47 c.1177-2A4G 2 0 0
BHD 48 c.1285dupC 1 0 0
BHD 49 c.1300G4C 1 0 0
BHD 51 c.1285dupC 1 0 0
BHD 53 c.871+3_871+4delGAins
TCCAGAT
1 0 0
BHD 57 c.250?_1740+?del
(del exon 5–14)
3 2 0
BHD 62 c.1301?_1740+?del
(del exon 12–14)
3 3 0
BHD 63 c.610_611delinsTA 2 1 1
BHD 66 c.3G4A 1 0 0
aDescribed by Leter et al, 2008. bDescribed by Johannesma et al, 2009.
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deletion. Analysis of these exon 1 deletions is ongoing. In the
cohort of our current study, no colorectal cancer was reported.
Colorectal adenomas were diagnosed by colonoscopy in four FLCN
mutation carriers (age 40, 42, 83, these patients were also included
in our previous reports by Leter et al, 2008 and Nahorski et al,
2010 and age 44, not reported previously).
Other malignancies than renal cancer were reported in six patients
previously documented in Leter et al (2008). In addition to the
patients reported by Leter et al (2008) in five patients without renal
cancer, tumours were reported including non-melanoma skin cancer
in two patients and single cases of melanoma, sarcoma, bladder and
prostate cancer. The patient diagnosed with melanoma was also
diagnosed with sarcoma. Three patients with renal cancer were
diagnosed with additional tumours. One patient had oncocytic
pituitary adenoma at age 9, astrocytoma at age 12, pheochromocy-
toma at age 34 and renal cancer at age 34 and 35 (BHD 63, Table 3).
No evidence for other tumour susceptibility was found. The other two
patients had gastric carcinoma at age 55 and renal cancer at age 56
(BHD 43, M, Table 3) and prostate carcinoma and renal cancer at age
50 (BHD 46, Table 3), respectively.
Renal manifestations
In all, 14 out of 115 (12%) FLCNmutation carriers from 12 families
were diagnosed with renal cancer. All available tumours were
revised at our center by two pathologists. In addition, one
mutation carrier had renal oncocytoma (BHD 57). Five mutation
carriers died of metastatic renal cancer (BHD 6, BHD 16, BHD 23,
BHD 37 and BHD 44; Table 3). All were diagnosed with renal
cancer after symptoms had developed. The histological classifica-
tion of the renal tumours according to the WHO criteria is shown
in Table 3 (Lopez-Beltran et al, 2009). Most of the tumours showed
cells with granular/floccular eosinophilic cytoplasm, as can be seen
in both clear cell carcinoma (formerly called the eosinophilic
variant, Table 3) and chromophobe carcinoma. This eosinophilic
cell variation is also often seen in sporadic clear cell carcinoma
(Kummerlin et al, 2009; Lopez-Beltran et al, 2009). As most
tumours had mainly eosinophilic cytoplasm, with moderately
sharp cell borders, a vague perinuclear halo and moderately
enlarged nuclei, we classified them as intermediate between clear
cell and chromophobe carcinoma (CC/Cph) (Table 3 and Figure 3).
c. 610_611delinsTA (1,14,16,29,31,36,43,63 N)
c.420delC (3 F)
c.469_471delTTC (M)
c.1285dupC (4,6,12,22,30,48,51 F)
c.1294_1298delTCCTC (35 F)
c. 1183_1198del (40 F)
c.[1301–7_1304del11;1323delCinsGA] 18 SS)c.319_320delGTinsCAC (23,37,44 F)
c. 655dupG (8 F) c. 1408_1418delGGGAGCCCTGT (27,46 F)c.3G>A (66,pMet1?, M)
4 5 6 7 8 9 10 11 12 13
c.619–1G>A (15,19,33 SS) Del 12–14 (62)c.1177–2A>G (47 SS)
/\/
c.1300G>C (49 SS)
c.871+3_c.871+4delGAinsTCCAGAT (53 SS)
/\/
Del 5–14 (57)
14
Figure 2 Overview of the FLCN mutations identified in this study. Del: deletion, F: frameshift, M: missense, N: nonsense, SS: splice site. Exons are depicted
as rectangles. The family numbers are shown after the mutations.
Table 3 Main features of 17 renal cancers in 14 FLCN germline mutation carriers from 12 BHD kindreds
Clinical characteristicsa
Family no. M/F Age at diagnosis (years) Diagnosisb Localisation Histology TNM Treatment Outcomec
BHD 1d F 60 B 1 (L) 1 CC/Cph T1N0M0 T A (3)
BHD 6d M 39 A 1 (R) 1 Pap/CC T3N2M1 T & Im D (40)
F 40 Ae 1 (L) 2 CC/Cph T2N0M0 T A (7)
BHD 16d M 56 A 1 (R) 1 CC/Cph/Sa T3N0M1 T & Ch D (57)
BHD 23 M 51 A 1 (L) 1 CC/Cph T1N0M1 T & Ch and Rth D (52)
BHD 32 F 51 B 1 (R) 1 CC/Cph T1N0M0 P A (3)
BHD 33 M 48 A 2 (L) 1 CC/Cph T3N0M0 T A (6)
51 B (R) 1 Unknown T1N0M0 P
BHD 35 M 38 A 2 (R) 2 CC T1N0M0 P A (1)
40 B (L) 2 Unknown T1N0M0 P
BHD 37 F 52 A 1 (L) 1 CC TxNxM1 Rth D (52)
BHD 43 F 74 A 1 (L) 2 CC/Cph T1N0M0 T A (3)
M 56 A 1 (R) 2 CC/Cph T1N0M0 T A (2)
BHD 44 F 43 A 1 (L) 1 CC/Cph TxNxM1 T and Me D (57)
BHD 46 M 50 A 1 (L) 1 Unclassifiedf T1N0M0 — D (50)
BHD 63 M 34 A 2 (L) 2 CC/Cph T2N0M0 T A (3)
35 B (R) 1 CC/Cph T1N0M0 P
Abbreviations: Ad¼ adenocarcinoma, classification not certain; BHD¼ Birt –Hogg–Dube´; CC¼ clear cell; CC/Cph¼ renal cell carcinoma with eosinophilic cytoplasm and
characteristics of both CC and Cph; Ch¼ chemotherapy; Cph¼ chromophobe; F¼ female; Im¼ immunotherapy; P¼ partial nephrectomy; M¼male; Pap¼ papillary;
Rth¼ radiotherapy; Me¼metastasectomy; Sa¼ sarcomatoid component; T¼ total nephrectomy; TNM¼ classification according to tumour/node/metastasis status.
aLocalisation: left column: 1/2: unilateral/bilateral, in parentheses: L/R: left-sided/right-sided, right column: 1: unifocal, 2: multifocal. Histology: according to Lopez-Beltran et al,
2009. bA: diagnosis after symptoms had developed; B: diagnosis after positive renal imaging of an asymptomatic individual. cA: alive, D: deceased; in parentheses: number of years
of follow-up and age at death, respectively. dDescribed by Leter et al, 2008. eCoincidental finding at medical examination for gastrointestinal complaints. fThe tumour was found
during autopsy and could not be reliably subclassified due to autolysis.
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One of the tumours showed sarcomatoid changes, which can
develop in both clear cell and chromophobe carcinoma (Table 3,
BHD 16). One other tumour had papillary structures in combina-
tion with clear cell changes (Table 3, BHD 6). Two additional
patients from FLCN positive families but with unknown mutation
carrier status (BHD 1 and BHD 42) were diagnosed with renal
cancer. These two tumours also showed mixed chromophobe/clear
cell histology. In all, 2 of the 14 renal tumours (BHD 1 and BHD 32,
Table 3) were detected by surveillance. For one of these patients
renal cancer was detected on the first ultrasound performed after
the diagnosis BHD was made (BHD 32, Table 3). For the other
patient renal cancer was detected by ultrasound 4 years after the
preceding normal ultrasound/MRI (BHD 1, Table 3); the latter
patient did not undergo standard yearly surveillance after the
initial imaging.
Cutaneous manifestations
Most FLCN mutation carriers (91/115, 79%), underwent dermato-
logical evaluation (68 of which were evaluated by dermatologists
at our center). In all 19 (21%) cases, aged 23–72 years, had no
cutaneous abnormalities; 14 (74%) of the patients without
cutaneous manifestations were over age 40. Notably, one patient
who presented with metastatic renal cancer at age 51 (BHD 23) had
no cutaneous lesions. The youngest mutation carrier with
histologically confirmed fibrofolliculomas was 25 years old (BHD
23). In five families without an identifiable FLCNmutation (BHD 2,
5, 9, 25 and 28) the clinical diagnosis BHD was based on
histologically confirmed multiple fibrofolliculomas; in one of these
kindreds both pneumothorax and renal cancer occurred (BHD 25,
Table 5). In seven families without FLCN mutations the skin
lesions consisted of multiple discoid fibromas of childhood onset
(families 11, 17, 20, 24, 38, 45 and 50). In two of these families
(24 and 45) a genealogical study showed common ancestry. No
renal or pulmonary signs were present in these seven families,
except for one case with pneumothorax. For two of these families
the FLCN-locus was excluded by linkage analysis (Starink et al, 2011).
Pulmonary manifestations
Among the 115 FLCN mutation carriers, 28 (24%) had a history of
pneumothorax, recurrent in eight patients (Table 4). In all, 4 out of
28 patients with a previous pneumothorax were confirmed
(former) smokers. The medical records of the other patients did
not state a history of smoking. The mean age of the first
pneumothorax was 36 years (range 18–74 years). We did not
systematically subject mutation carriers to CT scanning of the
lungs. For 12 FLCN mutation carriers the report of a CT-scan of
the thorax was available. Scans were performed either to confirm
suspected BHD or because of pulmonary complications of BHD. In
five of these patients (aged 25–46 years), multiple cysts were
reported in one or both lungs. Of these, two had a history of
recurrent or bilateral pneumothorax before the age of 30 years. In
seven FLCN mutation carriers no pulmonary cysts were detected
(age 23–71, four were over age 40).
Cumulative renal cancer and pneumothorax risk
The estimated renal cancer penetrance based on assessment of
FLCN mutation carriers only was 20% at age 70 (red dashed line,
Table 4 Main features of pneumothorax in 28 FLCN germline mutation
carriers from 15 BHD kindreds
Clinical characteristics
Family no. M/F
Age at
diagnosis R/L Episodes Renal cancer
BHD 1a F 44 L 1
M 30 R 1
BHD 14a M 36 L 1
BHD 15a F U U 1
BHD 16a M 67 L 1
F 47 U 1
BHD 18a M 22 U 1
BHD 23 M 22 L 1
BHD 29b M 25 B 5
M 27 B 1
BHD 32 F 39 U 1 51
F U U 1
M 23 U 1
BHD 33 M U U 1
BHD 35 M 38 R 2 38
BHD 37 F 48 B 1 51
F 29 R 1
BHD 63 M 37 B 1
BHD 62 M 53 L 7
M 27 L 1
M 42 B 3
BHD 43 F 38 L 1
M 37 R 4
F 74 L 1 74
M 32 L 3 55
F 18 R 2
BHD 57 M 31 L 1
F 33 R 5
Abbreviations: L¼ left lung; R¼ right lung; M¼male; F¼ female; B¼ bilateral;
U¼ available records did not state exact age/clinical characteristics. Age at diagnosis:
Age at diagnosis of the first episode of pneumothorax. Renal cancer: Age at diagnosis
of renal cancer in patients with a history of pneumothorax. aDescribed by Leter et al,
2008. bDescribed by Johannesma et al, 2009. The relative diagnosed with a clear cell
renal tumour was not tested for the FLCN mutation.
Table 5 Characteristics of BHD probands without an identified FLCN mutation
BHD no.
Sex and age
of proband Clinical characteristics Family data Remarks
BHD 2a M 46 years Multiple fibrofolliculomas on the face,
neck and trunk, starting at age 33 years
Colorectal cancer in mother Likely pathogenic FLCN exon 1 deletion and two
polymorphisms (IVS8+36G4A and IVS9+6C4T)b
BHD 5a M 33 years Multiple fibrofolliculomas on thorax since childhood Unclassified variant in FLCN: IVS8+36G4A
BHD 9a M 34 years More than 100 skin lesions on the face, neck and
trunk, fibrofolliculomas. ulcerative colitis, sacroiliitis
BHD 25 F 70 years Multiple fibrofolliculomas at age 66 years Nephew had pneumothorax
and died due to renal cancer
Likely pathogenic FLCN exon 1 deletion
BHD 28 M 56 years Multiple fibrofolliculomas since age 40 years
aDescribed by Leter et al, 2008. bIn BHD 2 an exon 1 deletion was detected in addition to two intronic FLCN variants, IVS9+6 C4T and IVS8+36G4A. Variant IVS9+6 C4T
was previously reported in a patient with suspected BHD who had multiple renal tumours (Gatalica et al, 2009). Both variants however, have since been reported to be rare
polymorphisms (https://grenada.lumc.nl/LOVD2/shared1/home.php?select_db¼ FLCN).
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Figure 1A). In contrast, when considering both tested and untested
relatives, the estimated renal cancer penetrance at age 70 was 16%
(continuous line, Figure 1A and B). The estimated penetrance for
the first episode of spontaneous pneumothorax was 29% (95%
minimal confidence interval: 9–49%, Figure 1C) at 70 years, again
considering information on both mutation carriers and their
untested relatives.
DISCUSSION
An important aim of this study was the estimation of renal cancer
and pneumothorax penetrance in BHD. By incorporating data on
relatives who did not undergo DNA testing we found an estimated
penetrance for renal cancer of 16% and a penetrance for
pneumothorax of 29% at the age of 70 years. The wide range of
prevalence for renal cancer among cohorts of BHD reported in
literature is 6.5–34% (Toro et al, 2007, 2008; Kunogi et al, 2010).
The renal cancer risk we found of around 16% at age 70 years is
important for counselling of FLCN mutation carriers and their
families ascertained in cancer family clinics. Future studies with
larger patient groups and comparison between cohorts investi-
gated in different populations may lead to further specification of
the renal cancer risk.
The clinical presentation, histological pattern and biological
behaviour of renal cancer in FLCNmutation carriers are important
for several reasons. First, a pathognomonic histological pattern
would be helpful for early diagnosis. Previously, The European
BHD Consortium proposed clinical diagnostic criteria for BHD,
which included early-onset, bilateral and multifocal renal tumours
and a mixed chromophobe and oncocytic histological pattern.
In addition, FLCNmutation analysis should be considered for patients
who have familial cystic lung disease, familial pneumothorax, familial
renal cancer, or any combination of spontaneous pneumothorax and
kidney cancer (Menko et al, 2009).
Notably, among 14 BHD patients in the current study who
developed renal cancer, clinical signs of hereditary disease (age at
onseto50 years and/or multifocal/bilateral tumours) were present
in only seven cases. In addition, the histological picture of BHD-
associated renal cancer in this cohort was not typical for this
syndrome. In all, 10 out of 14 renal tumours revised in this series
were difficult to classify. None of them showed classical features of
chromophobe renal cell carcinoma. Instead, they mainly exhibited
characteristics of both eosinophilic variants of clear cell cancer and
chromophobe carcinoma. One of the tumours was a hybrid form of
clear cell and papillary carcinoma and one showed sarcomatoid
changes. These histological patterns can also be found in sporadic
RCC. Therefore, late-onset unilateral, unifocal clear cell renal
cancer does not exclude BHD.
Furthermore, although BHD-associated renal tumours were
reported to metastasise rarely (Toro et al, 2008), 5 of the 14
patients with renal cancer in our cohort developed metastatic
disease underlining the importance of early detection of these
renal tumours by surveillance. In recently diagnosed families not
included in this report, we observed two BHD patients with renal
cancer at the ages of 30 and in the early twenties, respectively,
underlining that surveillance for renal cancer should be offered to
BHD patients from early age onward.
Of the 115 FLCN mutation carriers 28 had a history of
pneumothorax, frequently recurrent and bilateral. The mean ages
at which pneumothorax and renal cancer occurred in our cohort
were 36 and 49 years, respectively. Among the 14 renal cancer
patients described five had a history of pneumothorax (Tables 3
and 4), preceding renal cancer by several years in three patients
(BHD 32, 37, 43, Table 4). Although an increased risk for renal
cancer in BHD families with a positive history for pneumothorax
Figure 3 Illustration of the histological pictures of renal cell carcinomas in our series. (A) The most common pattern found, classified as clear cell/
chromophobe. The tumour cells show eosinophilic cytoplasm, moderate nuclear pleiomorphism, vague perinuclear halos, no explicit cell borders and no
vascular prominence. (B) Classical picture of clear cell carcinoma, as can be seen in many of the tumours in our series, but mostly only in part of the tumour
cells. (C) A clear cell/chromophobe renal cell carcinoma with partially clear cytoplasm, more prominent cell borders, no thick-walled vessels. (D) Renal cell
carcinoma with sarcomatoid changes (in the right part of the picture).
Renal cancer and pneumothorax risk in BHD
AC Houweling et al
1917
British Journal of Cancer (2011)105(12), 1912 – 1919& 2011 Cancer Research UK
G
e
n
e
ti
c
s
a
n
d
G
e
n
o
m
ic
s
has not been observed (Toro et al, 2008), bilateral, recurrent or
familial pneumothorax may serve as an early indicator of BHD
syndrome (Johannesma et al, 2009).
Ever since Hornstein and Knickenberg (1975) described the
combination of skin fibrofolliculomas and colorectal polyps it is a
matter of debate whether BHD is associated with an increased risk
of colorectal neoplasia. Although Zbar et al (2002) found no
significantly increased risk Khoo et al (2002) proposed that the
risk might apply to specific subgroups only. Nahorski et al (2010)
found evidence that the risk may be dependent on the FLCN
genotype. Recently, in family BHD15, one of the FLCN mutation
carriers developed symptomatic colonic cancer at age 62 years.
Late-onset colorectal cancer has been diagnosed in several other
FLCN mutation carriers from our BHD cohort not included in the
present study. Although colorectal cancer may well be coincidental
in these cases the current data call for further evaluation of the
colorectal neoplasia risk in BHD.
Among 27 families with clinical BHD (multiple fibrofolliculo-
mas) evaluated at our center 22 had pathogenic FLCN mutations,
resulting in a 81% yield for FLCN mutation analysis. Four patients
referred for suspected BHD declined genetic testing.
In two of the families (BHD 2 and 25) with clinical BHD but
without a mutation in the coding region of FLCN, a deletion of
exon 1 was observed. Exon 1 is the first of three non-coding exons.
The exact size and the effect of these deletions remain to be
determined. Recently, after completion of our study, intragenic
deletions and a duplication were reported in patients with BHD
(Benhammou et al, 2011). Using a luciferase reporter assay, this
study also showed that the expression was strongly reduced when
exon 1 was deleted. Analysis of the pathogenicity and co-
segregation of the deletions detected in our families are currently
ongoing to prove pathogenicity. Therefore, these families were not
included in the calculation of the penetrance for renal cancer and
pneumothorax, although the deletions are very likely to be
pathogenic. In the current study, intragenic deletions were
detected in two additional BHD families (BHD 57, 62), underlining
the importance of MLPA or CGH analysis in patients with a clinical
suspicion of BHD without an identifiable FLCN mutation.
Nine patients referred for possible BHD were diagnosed with
other conditions. One patient had probable tuberous sclerosis and
one patient had pulmonary emphysema. Seven of the families were
diagnosed with familial multiple discoid fibromas (FMDF). In
1985, one of the authors described this entity as a dominant
condition distinct from BHD, showing childhood onset, prefer-
ential localisation of lesions on the ears and distinct histology,
which mimics the trichodiscomas in BHD (Starink et al, 1985).
Thus far no systemic complications have been noted for FMDF
except for one patient with pneumothorax. We have now excluded
involvement of the FLCN locus in two FMDF kindreds using
linkage analysis (Starink et al, 2011).
Currently, we use the renal cancer risk of around 16% by
age 70 years for the counselling of patients to emphasise the
importance of surveillance for renal cancer. As according to our
histological data, the renal cancers found in BHD were not
evidently different from sporadic tumours, future studies aimed
at the classification of BHD-associated renal cancer in compar-
ison with sporadic disease are essential. Both the renal cancer
risk and the pneumothorax risk (about 16% and 29% at age
70 years, respectively) are based on a large set of data using a
model incorporating available data of family members not
subjected to DNA testing. Evaluation of larger patient groups
and patients from other populations may yield other penetrance
figures in the future.
The European BHD Consortium (Menko et al, 2009) proposed
FLCN mutation testing in patients with early-onset renal cancer
(o50 years), in particular with multifocal or bilateral disease
(or both) with chromophobe or oncocytic histology and in familial
renal cancer cases. Age at diagnosis of (the first) renal cancer in
our patient group was at or above 50 years of age in half of the
patients and the tumour histology was mixed in most patients but
included clear cell elements in all cases. Therefore, it will be
important to study the yield of FLCN mutation testing using a
wider set of criteria than proposed previously. The histology and
molecular pathology of renal tumours are associated with their
biological behaviour and reaction to systemic treatment of
metastatic disease. Therefore, additional studies are needed to
monitor the success of surveillance for renal cancer, the results of
surgical or other forms of local treatment such as radiofrequency
ablation and response to targeted therapies.
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